Literature DB >> 14669829

Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro.

R D Orkin1, D I New, D Norman, S L Chew, A J L Clark, A B Grossman, M Korbonits.   

Abstract

Ghrelin, the recently identified hormone with GH-secreting and appetite-inducing effects, acts on the GH secretagogue receptor (GHS-R). GHS-R belongs to the G protein-coupled 7 transmembrane domain receptors and activates the phospholipase C pathway; it then leads to the release of GH from somatotroph cells via an elevation of intracellular calcium concentration. Both in vivo and in vitro studies demonstrated that the effect of GH secretagogues (GHS) could be desensitised similar to most receptor stimulation systems. We have studied whether acute desensitisation of the GHS-R occurs in response to the GHS hexarelin in vitro in terms of intracellular calcium concentration. Chinese hamster ovary cells were transiently transfected with cDNA encoding the human type 1a GHS-R. The presence of messenger RNA was confirmed with RT-PCR, while no GHS-R was observed in mock-transfected cells. Calcium responses to the peptide GHS analogue hexarelin were measured using the fluorescent indicator fura-2. Cells were stimulated with the peptide GHS, hexarelin, at concentrations between 10(-10) and 10(-7) M. Cells transfected with the GHS-R cDNA demonstrated a significant and specific calcium response to hexarelin that was not observed in mock-transfected cells. Marked desensitisation of the calcium response to hexarelin was observed 2-5 min after the first dose of hexarelin (10(-7) M) was administered. These data show directly for the first time the desensitisation of the GHS receptor signal at the second messenger level. The desensitisation of the receptor may play a major role in the regulation of effect of circulating or locally produced ghrelin both in the GH and in the appetite-regulating system or in other systems where ghrelin has been shown to be active, such as the cardiovascular system or cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669829     DOI: 10.1007/BF03347357

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  Growth hormone status during long-term hexarelin therapy.

Authors:  A Rahim; P A O'Neill; S M Shalet
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

2.  Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon.

Authors:  S Freier; O Weiss; M Eran; A Flyvbjerg; R Dahan; I Nephesh; T Safra; E Shiloni; I Raz
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

3.  Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites.

Authors:  A D Blake; R G Smith
Journal:  J Endocrinol       Date:  1991-04       Impact factor: 4.286

4.  Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children.

Authors:  B Klinger; A Silbergeld; R Deghenghi; J Frenkel; Z Laron
Journal:  Eur J Endocrinol       Date:  1996-06       Impact factor: 6.664

5.  On the actions of the growth hormone-releasing hexapeptide, GHRP.

Authors:  C Y Bowers; A O Sartor; G A Reynolds; T M Badger
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

6.  Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation.

Authors:  W K DeBell; S S Pezzoli; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

7.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

8.  A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men.

Authors:  E A Nijland; C J Strasburger; C Popp-Snijders; P S van der Wal; E A van der Veen
Journal:  Eur J Endocrinol       Date:  1998-10       Impact factor: 6.664

9.  Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children.

Authors:  V Mericq; F Cassorla; T Salazar; A Avila; G Iñiguez; C Y Bowers; G R Merriam
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

10.  Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.

Authors:  C A Jaffe; P J Ho; R Demott-Friberg; C Y Bowers; A L Barkan
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

View more
  4 in total

1.  Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro.

Authors:  T Kitazawa; B De Smet; K Verbeke; I Depoortere; T L Peeters
Journal:  Gut       Date:  2005-04-20       Impact factor: 23.059

2.  Ghrelin in female and male reproduction.

Authors:  Joëlle Dupont; Virginie Maillard; Stéphanie Coyral-Castel; Christelle Ramé; Pascal Froment
Journal:  Int J Pept       Date:  2010-03-14

3.  Ghrelin improves delayed gastrointestinal transit in alloxan-induced diabetic mice.

Authors:  Wen-Cai Qiu; Zhi-Gang Wang; Ran Lv; Wei-Gang Wang; Xiao-Dong Han; Jun Yan; Yu Wang; Qi Zheng; Kai-Xing Ai
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 4.  From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.

Authors:  Ken Howick; Brendan T Griffin; John F Cryan; Harriët Schellekens
Journal:  Int J Mol Sci       Date:  2017-01-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.